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Abstract: Plasma extracellular vesicles (EVs) are lipid membrane vesicles involved in several
biological processes including coagulation. Both coagulation and lipid metabolism are strongly
associated with cardiovascular events. Lowering very-low- and low-density lipoprotein ((V)LDL)
particles via dextran sulphate LDL apheresis also removes coagulation proteins. It remains unknown,
however, how coagulation proteins are removed in apheresis. We hypothesize that plasma EVs that
contain high levels of coagulation proteins are concomitantly removed with (V)LDL particles by
dextran sulphate apheresis. For this, we precipitated (V)LDL particles from human plasma with
dextran sulphate and analyzed the abundance of coagulation proteins and EVs in the precipitate.
Coagulation pathway proteins, as demonstrated by proteomics and a bead-based immunoassay,
were over-represented in the (V)LDL precipitate. In this precipitate, both bilayer EVs and monolayer
(V)LDL particles were observed by electron microscopy. Separation of EVs from (V)LDL particles
using density gradient centrifugation revealed that almost all coagulation proteins were present
in the EVs and not in the (V)LDL particles. These EVs also showed a strong procoagulant activity.
Our study suggests that dextran sulphate used in LDL apheresis may remove procoagulant EVs
concomitantly with (V)LDL particles, leading to a loss of coagulation proteins from the blood.
Int. J. Mol. Sci. 2018, 19, 94; doi:10.3390/ijms19010094 www.mdpi.com/journal/ijms
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1. Introduction
Circulating extracellular vesicles (EVs) have been recognized for their emerging roles in
(patho)physiology and their potential as biomarkers in cardiovascular disease [1,2]. We have
shown that cardiovascular events, such as myocardial infarction and stroke, are associated with
coagulation-pathway proteins that are carried by the plasma EVs [3,4]. Tissue factor, which plays
a central role in thrombus formation, is also carried in the blood by EVs [5–7]. Furthermore,
the concentration of plasma EVs is positively correlated with total thrombin generation in individuals
with familial hypercholesterolemia [8].
High levels of low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) cholesterol
are associated with an increased risk of cardiovascular events [9,10]. For most hypercholesterolemic
patients, a standard diet and lipid-lowering drug therapy are recommended. However, patients
with severe hypercholesterolemia, such as homozygous familial hypercholesterolemia, may require
additional treatment, such as LDL apheresis, a procedure that eliminates LDL and VLDL from the
blood [11–15]. One of the most commonly used methods, dextran sulphate adsorption (DSA), has been
reported to deplete blood coagulation factors [16–19]. Furthermore, it was shown that both the extrinsic
and intrinsic coagulation pathways were disturbed by LDL apheresis [18]. Depletion of coagulation
factors by apheresis is assumed to reduce blood viscosity and improve regional myocardial perfusion
in patients with severe hypercholesterolemia [20,21].
Connolly and colleagues showed that the concentration of plasma EVs in patients with familial
hypercholesterolemia was reduced after LDL apheresis [8]. The content of these apheresis-depleted
plasma EVs, however, has not been characterized. Therefore, it remains unclear if coagulation proteins
are present in the plasma EVs and whether these EVs have coagulation activity. We hypothesize
that besides (V)LDL, a subset of plasma EVs containing high levels of coagulation proteins will be
removed from the blood during DSA LDL apheresis. In this study, we precipitated (V)LDL particles
from human plasma using dextran sulphate (as an in vitro model for DSA apheresis) followed by
a proteomic analysis of the content and a measurement of the pro-coagulant activity of precipitated EVs.
2. Results
2.1. Coagulation Protein Levels in the (V)LDL (Very-Low- and Low-Density Lipoprotein) Precipitate
Label-free proteomics was performed on both (V)LDL- and high-density lipoprotein
(HDL)-precipitates. Protein levels in the HDL-precipitate were used as reference for proteomic
analysis. The proteomic analysis showed that 144 proteins were exclusively present in the (V)LDL
precipitate (Supplementary Table S1). Using Ingenuity Pathway Analysis (IPA), three canonical
pathways were over-represented in the (V)LDL precipitate: coagulation system, extrinsic thrombin
activation, and intrinsic thrombin activation (Table 1).
Four proteins present in the IPA coagulation system pathway were selected for verification
using a bead-based immunoassay: von Willebrand factor (VWF), SerpinC1, plasminogen (PLG),
and SerpinF2. The selection of these four proteins was based on the availability of antibodies and
recombinant proteins needed for the assay. The protein levels of VWF, SerpinC1, PLG, and SerpinF2
were significantly higher in the (V)LDL precipitate compared to the HDL precipitate (Figure 1).
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Coagulation System 10.26 2.93
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Intrinsic Prothrombin Activation 6.01 1.92
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high-density lipoprotein (HDL) precipitates. von Willebrand factor (VWF), SerpinC1, plasminogen 
(PLG) and SerpinF2 levels in the (V)LDL and HDL precipitates were determined by multiplex 
immunoassay and normalized to the original volumes of plasma. n = 20, *** p < 0.001 compared to the 
respective protein levels in the HDL precipitate. Bars represent mean ± standard error of mean 
(S.E.M). 
2.2. Bilayer EVs Co-Precipitate with Lipoprotein Particles 
Since EVs have been reported to contain coagulation proteins [5,7], we suspected that plasma 
EVs might be concomitantly precipitated with (V)LDL particles by dextran sulphate (DS). As 
expected, monolayer lipoprotein particles with distinct characteristics under the electron microscope 
(EM) [22,23] were present in the (V)LDL precipitate (Figure 2). In addition, bilayer membrane 
vesicle-like structures were observed in the plasma (V)LDL precipitate under EM (Figure 2). Those 
structures showed clear lipid bilayers at a magnification of 87,000× and had a size of 60–100 nm in 
diameter, identifying the presence of EVs in the (V)LDL precipitate. 
 
Figure 2. The presence of extracellular vesicles (EVs) in the (V)LDL precipitate. (V)LDL precipitate 
was processed for electron microscopy as described in the Materials and Methods section. Black 
arrows indicate bilayer EVs of 60–100 nm in diameter. The blank arrow indicates monolayer 
lipoprotein particles. Scale bar = 100 nm. 
Figure 1. Coagulation proteins enriched in the very-low- and low-density lipoprotein ((V)LDL) and
high-density lipoprotein (HDL) precipitates. von Willebrand factor (VWF), SerpinC1, plasminogen
(PLG) and SerpinF2 levels in the (V)LDL and HDL precipitates were determined by multiplex
immunoassay and normalized to the origin l volum s of plasma. n = 20, *** p < 0.001 compared
to the respective protein levels in the HDL precipitate. Bars represent mean ± standard error of
mean (S.E.M).
2.2. Bilayer EVs Co-Precipitate with Lipoprotein Particles
Since EVs have been reported to contain coagulation proteins [5,7], we suspected that plasma EVs
might be concomitantly precipitated with (V)LDL particles by dextran sulphate (DS). As expected,
monolayer lipoprotein particles w th distinct charac eristics under the electron microscope (EM) [22,23]
were present in the (V)LDL precipitate (Figure 2). In addition, bilayer membrane vesicle-like structures
were observed in the plasma (V)LDL precipitate under EM (Figure 2). Those structures showed clear
lipid bilayers at a magnification of 87,000× and had a size of 60–100 nm in diameter, identifying the
presence of EVs in the (V)LDL precipitate.
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Figure 2. The pre ence of extracellular vesicle (EVs) in the (V)LDL precipitate. (V)LDL precipitate was
processed for electron microscopy as described in the Materials and Methods section. Black arrows
indicate bilayer EVs of 60–100 nm in diameter. The blank arrow indicates monolayer lipoprotein
particles. Scale bar = 100 nm.
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2.3. Coagulation Proteins in the (V)LDL Precipitate are Present in Extracellular Vesicles (EVs)
Having shown that coagulation pathways and four coagulation proteins were over-represented
in the (V)LDL precipitate that contains EVs (Figures 1 and 2), we further investigated whether these
coagulation proteins were present in EVs or in lipoprotein particles. For this, we separated lipoprotein
particles from EVs using density gradient centrifugation. Lipoprotein particles were enriched in the
4th sub-fraction (density 0.98 g/mL) as shown by the presence of the (V)LDL marker apolipoprotein B
(ApoB) protein [24] (Figure 3A). The four selected coagulation pathway proteins VWF, SerpinC1, PLG,
and SerpinF2 were mainly present in the 6th–8th sub-fractions (density 1.02–1.08 g/mL) (Figure 3A).
Enrichment of (V)LDL particles and EVs in different sub-fractions was confirmed by EM, which showed
(V)LDL particles in the 4th sub-fraction (Figure 3B,B’) and bilayer EVs in the 6th–8th sub-fractions
(Figure 3C). Abundance of EVs in the 6th–8th sub-fractions was further confirmed by Western blotting
for a canonical EV marker, the cluster of differentiation molecule 9 (CD9) [25–27] (Figure S1).
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Figure 3. Distribution of VWF, SerpinC1, PLG, SerpinF2, and ApoB in density sub-fractions of
the (V)LDL precipitate after density gradient centrifugation. * V1, the first sub-fraction of (V)LDL
precipitate. The density of each sub-fraction was indicated accordingly. ** The unit of density is g/mL.
(A) Protein levels of VWF, SerpinC1, PLG, and SerpinF2 are presented as the percentage of the 8th
sub-fraction (V8). Protein levels of ApoB are presented as the percentage of the 4th sub-fraction (V4).
(B) A representative electron microscope (EM) image of the 4th sub-fraction shows lipoprotein particles.
Scale bar = 500 nm. (B’) Larger magnification of insert in (B). Scale bar = 50 nm. (C) A representative
EM image of the 7th sub-fraction shows EVs. Scale bar = 100 nm.
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2.4. Procoagulant Activity
Since coagulation pathway proteins were mainly present in the EV-rich 6th–8th sub-fractions of
(V)LDL precipitate after density gradient centrifugation, we measured the procoagulant activity of
each sub-fraction. Among the 10 sub-fractions, the 6th–8th sub-fractions contained abundant EVs
and had the highest procoagulant activity (Figure 4 and Table 2). In contrast, the 4th sub-fraction that
was enriched with (V)LDL particles showed very low procoagulant activity (less than 10% of total
procoagulant activity in the precipitate, Figure 4).
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Bars represent mean ± S.E.M. Student’s t-test compared to V4, ** p < 0.01, *** p < 0.001.
Table 2. Procoagulant activity in the density gradient sub-fractions of the (V)LDL precipitate.
Sub-Fraction of (V)LDL Precipitate Factor Xa Generation (fM Xa/min)
V1 145.67 ± 44.98
V2 101.17 ± 30.21
V3 124.58 ± 33.16
V4 673.75 ± 153.93
V5 239.67 ± 57.03
V6 1592.17 ± 304.77 *
V7 2028.33 ± 324.72 **
V8 1596.83 ± 272.50 *
V9 223.25 ± 72.88
V10 309.42 ± 148.90
Total 7034.83 ± 1237.64
Data are presented as mean ± S.E.M. Student’s t-test compared to V4, * p <0.05, ** p <0.01.
3. Discussion
Coagulation and lipid metabolism are two prominent processes involved in the progression of
atherosclerosis leading to cardiovascular events such as myocardial infarction and stroke. Plasma
EVs have been reported to contain coagulation proteins [5,7] and participate in blood coagulation [28].
We now show that plasma EVs co-precipitated with (V)LDL particles by dextran sulphate (DS) are
enriched with coagulation proteins nd have procoagul t activity.
LDL apheresis, a well-established lipid-lowering therapy, has been know for decades to reduce
LDL as well as coagulation factors [16–19]. DSA, one of the most widely used methods of LDL
apheresis, acutely reduces coagulation factors, such s factor V, VIII, and XI [17,29]. A recent study
reported that a p pulation of EVs (200–250 nm) was r duced in plasma after apheresis [8]. However,
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the EVs depleted by apheresis have not been isolated and characterized. For this, it remains unclear
if coagulation proteins are associated with DS-precipitated (V)LDL particles or plasma EVs, or are
directly bound to DS. To address these questions, we obtained (V)LDL precipitate from plasma by
using DS to mimic DSA apheresis in vitro. In line with DSA LDL apheresis [17,29], coagulation
pathway proteins were significantly over-represented in the (V)LDL precipitate compared to HDL
precipitate. An EM revealed that the (V)LDL precipitate contained both lipoprotein particles and EVs.
Distinct from (V)LDL particles that have a monolayer lipid membrane [22,23], the EVs co-precipitated
with (V)LDL particles have a bilayer-membrane and express CD9 [25–27,30] (Figures 2, 3 and S1).
Density gradient centrifugation separating (V)LDL particles from EVs showed that the selected
four coagulation pathway proteins (VWF, SerpinC1, PLG, and SerpinF2) were present in EVs (Figure 3).
This strongly suggests that the removal of coagulation factors by LDL apheresis was due to the
removal of EVs from the blood. This is in agreement with the finding that the four coagulation-related
proteins (VWF, SerpinC1, PLG, and SerpinF2) identified in the (V)LDL co-precipitated EVs were also
retained in the DSA cellulose column during apheresis in severe hypercholesterolemic patients [17].
Furthermore, the procoagulant activity was predominantly detected in the (V)LDL co-precipitated
EVs (Figure 4), in line with the higher thrombin generation potential of smaller EVs [8]. A minor part
of the coagulation proteins and procoagulant activity were associated with the ApoB-positive (V)LDL
fraction (Figures 3 and 4 and Table 2). For this, we cannot rule out that some of the coagulation proteins
might be associated with circulating (V)LDL particles. The marginal procoagulant activity of the
(V)LDL sub-fraction is presumably due to the lipid membrane that provides a surface for coagulation
machinery [31].
Coagulation, anti-coagulation, and fibrinolysis systems are highly regulated and interact to
maintain physiological hemostasis. EVs co-precipitated with (V)LDL particles host all three systems
regulating the formation and resolution of blood clot (Figure 5). EVs are enriched with coagulation
proteins such as VWF, which plays a major role in coagulation by carrying coagulation factor VIII to
prevent its premature clearance and recruiting platelets from the circulation to form a hemostatic plug at
the damaged site of a blood vessel. Defects in VWF could lead to bleeding disorders [32,33]. SerpinC1,
also known as anti-thrombin, plays an important role in anti-coagulation by inhibiting thrombin,
factor Xa, and factor IXa [34]. PLG, the inactive form of plasmin that is important in fibrinolysis,
can be activated by tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator
(uPA) [35]. SerpinF2, also known as α2-antiplasmin, is a specific inhibitor of plasmin [35]. As plasmin
promotes the degradation of the hemostatic clots, the abundance of PLG and SerpinF2 suggests
an anti-fibrinolytic property of EVs.
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The prominent procoagulant activity (Figure 4) in the EV fractions suggests that the EVs
co-precipitated with (V)LDL particles may contain coagulation factor VII and tissue factor.
This would be similar to plasma EVs in sepsis and cancer patients that have been shown to contain
coagulation factor VII and tissue factor [6,36]. Next to this, EVs have a negatively charged lipid
membrane that might serve as a surface for assembling the coagulation machinery [31]. Given that
determination of the origin of EVs is challenging [26,30], the origin of (V)LDL co-precipitated EVs was
not investigated in the current study. In light of their prominent procoagulant activity, we suspect that
(V)LDL co-precipitated EVs are likely derived from endothelial cells and/or monocytes [1,30,37].
The co-precipitation of EVs and lipoprotein particles by dextran sulphate, a negatively charged
polysaccharide, points to an unknown shared property by the two distinct membrane vesicles.
Given the content and procoagulant activity of (V)LDL co-precipitated EVs, one may postulate that
concomitant removal of those EVs during apheresis may contribute to the clinical benefits of apheresis
beyond lipid lowering [8]. Apheresis, however, is only used in a small group of patients with severe
hypercholesterolemia [11–15]. Statins, a class of drugs that reduce (V)LDL by inhibiting the production
of cholesterol, are now also considered as antithrombotic drugs [38]. It is therefore tempting to propose
that the antithrombotic pleiotropic effect of statins might be attributed to the modulation of EVs.
Further research, however, is needed to evaluate if statin therapy would also affect coagulation protein
content and coagulation activity in plasma EVs.
A limitation of this study is that since only healthy subjects were enrolled, the pathophysiological
and biomarker roles of (V)LDL co-precipitated EVs in cardiovascular disease [1] remain unclear.
Studies on patients subjected to LDL apheresis are therefore needed. A better understanding of how
(V)LDL co-precipitated EVs impacts the balance of pro- and anti-coagulation in various organ systems
may lead to the design of molecular interventions via EVs to prevent thrombosis or control bleeding.
Furthermore, following the example of cancer therapeutics [39], personalized medicine approaches
based on (V)LDL co-precipitated EVs may allow for the assessment of susceptibility to coagulation
from quantifying EV content, or allow the design of optimal EV-content for therapeutically attenuating
these processes.
4. Materials and Methods
4.1. Study Subjects and Sample Preparation
Plasma from 20 healthy volunteers (10 male and 10 female, average age 30.3± 8.2 years) was used
for this study. Blood was collected into ethylenediaminetetraacetic acid (EDTA) tubes and centrifuged
at 2000 g for 10 min at 4 ◦C as previously described [40]. The plasma was collected and stored at−80 ◦C
for further analysis. This study was approved by the institutional review board (IRB, institutional
ethics committee, B-15-094, 18 September 2015) of the National University of Singapore, and written
informed consent was obtained from all participants according to the Declaration of Helsinki.
4.2. Sequential Precipitation of (V)LDL Fraction and HDL Fraction
(V)LDL and HDL fractions were selectively precipitated as previously described [40,41].
Briefly, 6.5% (w/v) dextran sulphate (DS) and 2 M Manganese (II) chloride (MnCl2) (Sigma-Aldrich,
St. Louis, MO, USA) stock solutions were prepared in Milli-Q H2O. To precipitate (V)LDL fraction,
DS stock solution (1:125) and MnCl2 stock solution (1:40) were added to plasma. The plasma sample
was vortexed and centrifuged at 4800 g for 10 min at 4 ◦C. The pellet was collected as (V)LDL fraction
and the supernatant was transferred to a new tube. DS stock solution (1:10) and MnCl2 stock solution
(1:10) were added to the supernatant. The sample was vortexed and then incubated for 2 h at 4 ◦C.
After incubation, the HDL fraction was isolated by centrifugation at 4800 g for 10 min at 4 ◦C.
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4.3. Proteomics and IPA Analysis
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used for label-free
proteomic analysis as described [42]. Briefly, LC-MS/MS (Agilent Technologies Inc.,
Santa Clara, CA, USA) was used to analyze purified proteins from the (V)LDL and HDL precipitates.
The two precipitates (approximately 50 µg each) were resolved in two lanes of a 10% SDS-PAGE
gel (Bio-Rad, Hercules, CA, USA), respectively, and subsequently stained with Coomassie blue.
Each lane was excised after gel destaining and divided into six pieces equally for in-gel trypsin
digestion; after reduction with 20 mm dithiothreitol (DTT) and alkylation using 55 mm iodoacetamide
(IAA), each piece was digested with sequencing-grade trypsin (Promega, Madison, WI, USA)
overnight. Digested peptides were extracted from the gel, dried, and then desalted. The peptides
were analyzed with a Q-Exactive mass spectrometer (Thermo Scientific, San Jose, CA, USA)
coupled with an Ultimate 3000 RSLC nano-HPLC system (Dionex, Amsterdam, The Netherlands).
The raw data were converted to mascot generic (mgf) files using Proteome Discoverer ver. 1.4
(Thermo Scientific, San Jose, CA, USA), and then the mgf files were searched against the Uniprot
human proteome database (Released on 29 November 2013; 176,946 sequences, 70,141,034 residues)
using an in-house Mascot Server ver. 2.4.1 (Matrix Science, London, UK).
Ingenuity Pathway Analysis (IPA®, QIAGEN, Redwood City, CA, USA, Build Version 321501M,
Content Version 17199142) was used to determine canonical pathways statistically over-represented
in the proteins that were only in the (V)LDL precipitate. Proteins of pathways significantly
over-represented were selected for verification based on antibody and recombinant protein availability
to set up the multiplex immunoassay.
4.4. Quantitative Measurement of Protein Levels
Protein levels were determined using a bead-based immunoassay as previously described [3].
In short, the beads (Luminex #MagPlex-C Microspheres, MC100-xx, Austin, TX, USA) were
conjugated with selected antibodies to form a bead-capture antibody complex. Samples were
incubated with the bead-capture antibody complex followed by the biotinylated antibodies.
Streptavidin-phycoerythrin (SA-PE, BD Bioscience #554061, San Jose, CA, USA) was added to
quantify the concentration of captured proteins. Standard dilution curves for homologous
recombinant proteins were correlated to the SA-PE signal. Data were acquired and analyzed
with the Bio-Plex® 200 Systems (Bio-Rad #171-000201, Hercules, CA, USA). The antibodies and
recombinant proteins were listed as follows. Detection of von Willebrand factor (VWF) used
recombinant human VWF protein (Factor VIII free, Fitzgerald #30C-CP4003U, Fitzgerald Industries
International, Acton, MA, USA), anti-human VWF (Fitzgerald #70R-10589, Fitzgerald Industries
International, Acton, MA, USA), and biotinylated anti-human VWF (Fitzgerald #60R-1019, Fitzgerald
Industries International, Acton, MA, USA); detection of SerpinC1 used antithrombin III antibody
(NOVUS Biologicals #NBP1-05149, Littleton, CO, USA), human SerpinC1 biotinylated affinity
purified antibody (R&D Systems #BAF1267, Minneapolis, MN, USA), and recombinant human
SerpinC1 (R&D Systems #1267-PI-010, Minneapolis, MN, USA); detection of plasminogen used
anti-human plasminogen (HyTest #4P11, Turku, Finland), biotinylated anti-human plasminogen
(HyTest #4P11B, Turku, Finland), and recombinant human plasminogen (BBI Solutions #P204-1;
Cardiff, UK); and detection of SerpinF2 used anti-human SerpinF2 (R&D Systems #MAB1470,
Minneapolis, MN, USA), biotinylated anti-human SerpinF2 (R&D Systems #BAF1470, Minneapolis,
MN, USA), and recombinant human SerpinF2 (R&D Systems #1470-PI-010, Minneapolis, MN, USA).
This assay is referred to as a multiplex immunoassay.
4.5. Apolipoprotein B Measurement
Apolipoprotein B (ApoB) was measured in triplicate with an ELISA kit (R&D Systems #DAPB00,
Minneapolis, MN, USA) according to the manufacturer’s instructions.
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4.6. Density Gradient Centrifugation
(V)LDL precipitate was isolated from 8 mL plasma as described above. In order to make the
density gradient buffer, five solutions containing different concentrations of OptiPrepTM medium
(OptiPrep, Axis-shiled #1114542, Oslo, Norway) were prepared with 10× PBS pH 7.4 (Ambion®,
Life Technologies #AM9265, Carlsbad, CA, USA) and Milli-Q H2O. The working solutions comprised
5%, 10%, 20%, 30%, and 40% OptiPrep and 1× PBS respectively. The solutions were added and
overlaid into the ultracentrifuge tubes (Beckman Coulter #344059, Brea, CA, USA) sequentially with
the highest density (40% OptiPrep) on the bottom. Subsequently, the isolated (V)LDL precipitate was
carefully placed on top of the density gradient buffer followed by centrifugation at 200,000 g for 18 h
at 4 ◦C with low acceleration and low brake (Beckman Coulter #Optima XL-90 Ultracentrifuge #SW 41
Ti Rotor, Brea, CA, USA). Afterwards, 10 different gradient sub-fractions (1 mL per sub-fraction) were
harvested sequentially (from top to bottom) and transferred into 1.5-mL Eppendorf tubes.
After thorough vortexing, 900 µL of each sub-fraction was transferred into a new ultracentrifuge
tube, respectively, containing 7 mL 0.1% BSA buffer (Sigma-Aldrich #05470, in 1× PBS, m/v,
St. Louis, MO, USA), and centrifuged at 200,000 g for 1 h at 4 ◦C. The pellets were resuspended
in 200 µL lysis buffer (Roche #04719956001, Basel, Switzerland) for protein level measurement or in
200 µL 1× PBS for procoagulant activity assay. The remaining 100 µL of the sub-fractions were used
for density measurement and electron microscopy.
4.7. Electron Microscopy
Both the (V)LDL precipitate (resuspended in 1× PBS) and its sub-fractions from density gradient
centrifugation (100 µL leftover of each sub-fraction) were processed at room temperature (20 ◦C)
for electron microscopy (EM). The samples were diluted 1:5 in 1× PBS prior to fixation with
2.0% glutaraldehyde (Sigma-Aldrich #G5882, St. Louis, MO, USA). After fixation, a 75-mesh grid
(Agar scientific #G2075C, Stansted, UK) was laid on a drop of sample for 10 min; then, the grid
was rinsed 10 times with Milli-Q H2O (1 min per rinse). For staining, the grid was firstly laid on
a drop of uranyl acetate (pH 7.0, SPI-CHEM #2624, West Chester, PA, USA) for 10 min. The grid was
subsequently rinsed with Milli-Q H2O and methylcellulose uranyl (pH 4.0), and then incubated for
10 min on a drop of methylcellulose uranyl (pH 4.0, Sigma-Aldrich #M-6385, St. Louis, MO, USA).
The samples were analyzed with an FEI Tecnai™ T12 electron microscope (FEI Company, Eindhoven,
The Netherlands).
4.8. EV Associated Procoagulant Activity Assay
Sub-fractions of (V)LDL precipitate obtained by density gradient centrifugation were resuspended
in 200 µL PBS. EV-associated procoagulant activity was measured as previously described with
adaptations [43,44]. Briefly, 20 µL of each sub-fraction in PBS was incubated for 15 min in
100 µL incubation buffer containing 10 mM HEPES, 25 µM negatively charged phospholipids
(dioleoylphosphatidylserine and dioleoylphosphatidylcholine at 1:9, Avanti Polar Lipids #840035P,
#850375P, Alabaster, AL, USA), 137 mM NaCl, 4 mM KCl, 6 mM CaCl2, 5 mg/mL bovine serum
albumin, and 5 units/mL hirudin (Sigma-Aldrich #H0393, pH 7.45, St. Louis, MO, USA). Subsequently,
40 µL 5.63 nM Factor VII (Enzyme Research Laboratories #HFVII1007, South Bend, IN, USA) or
incubation buffer was added and the mixture was incubated at room temperature for 10 min.
After incubation, 25 µL Factor Xa chromogenic substrate S2765 (Chromogenix #82141339, Werfen,
Barcelona, Spain) was added followed by 40 µL of 281 nM Factor X (Enzyme Research Laboratories
#HFX1010, South Bend, IN, USA) to start the reaction. The rate of the chromophoric group
p-nitroaniline formation was recorded for 90 min at 405 nm and the rate of Factor Xa generation
was calculated. Procoagulant activity was expressed as the rate of Factor Xa generation in fM
Xa/min. Recombinant human tissue factor (Dade® Innovin, Siemens Healthcare Diagnostics #B4212,
Tarrytown, NY, USA) was used as a positive control.
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4.9. Statistics
EV protein levels in the (V)LDL precipitate and HDL precipitate were analyzed using a paired
t-test as each pair of (V)LDL and HDL fractions was from individual subjects. All statistical analysis
was performed using SPSS® (IBM®, Version 22.0.0.0; Armonk, NY, USA).
5. Conclusions
Procoagulant EVs are concomitantly precipitated with (V)LDL particles from plasma by dextran
sulphate used in LDL apheresis. Our findings suggest that a loss of coagulation factors and coagulation
activity during LDL apheresis may be explained by the concomitant removal of procoagulant EVs and
(V)LDL particles.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/1/94/s1.
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